Have questions? reach out
Have questions? reach out
After identifying your targets of interest—through WBL services or other methods—our scientists collaborate with you to develop customized targeting solutions optimized for your project’s goals.
[ Biomarker Discovery ]
[ Targeted Sequencing ]
[ Deployment ]
After identifying your targets of interest—through WBL services or other methods—our scientists collaborate with you to develop customized targeting solutions optimized for your project’s goals.
Meet with our team to explore your therapeutic area of interest, establish clear objectives, and determine the optimal approach for your desired endpoints.
Leverage our biomarker discovery services to identify genes, regions, or other genomic features critical to your project.
Utilize hybridization-based enrichment with optimized oligonucleotide probes or bioinformatic targeting to analyze specific regions of interest.
Meet with our team to explore your therapeutic area of interest, establish clear objectives, and determine the optimal approach for your desired endpoints.
RUO
GCP
CLIA (NYS)
[Solution 01]
WBL offers custom bioinformatic solutions to balance breadth, precision, and efficiency for genomic and methylation panels. Pairing biomarker discovery services with custom bioinformatic pipelines to target regions of interest, WBL’s approach reduces noise and redundancy, delivering high-quality results for methylation and native DNA studies at any scale.
Figure 2A. Quantitative Identification of Tissue-Specific Methylation with dMS. Correlations between predicted and actual fractions of Tissue 1-derived DNA show high accuracy with 2,000 randomly selected reads, demonstrating the precision of dMS
Figure 2B. Sensitive Detection of Low-Concentration DNA with dMS. dMS achieves accurate detection of Tissue 1-specific DNA at low concentrations, with high correlation (R² = 0.997) even with fewer than 100 reads per dilution.
Identifying DNA’s cell or tissue of origin through methylation analysis has significant clinical applications, but its use in diagnostics has been limited by bisulfite sequencing biases and restricted target coverage. WBL’s dMS enables precise tissue-of-origin determination by detecting complex tissue-specific methylation signatures.
DNA from Tissue 1 and Tissue 2 was sequenced with dWMS. Bioinformatic targeting of 8,457 Tissue 1-specific regions allowed accurate identification (Figure 2A, 2B).
From exploratory research to targeted analyses, Wasatch BioLabs empowers precision analysis with unbiased sequencing solutions. Leveraging proprietary technologies like dTMS, tailored workflows, and expert bioinformatics support, we deliver actionable insights to advance your research.
[Service]
Harness advanced tools like dTMS to develop targeted panels, analyze complex variants, and detect epigenetic modifications with scalable workflows for clinical applications.
[Service]
Enhance your data with custom bioinformatics solutions, using tailored workflows and advanced analysis to generate impactful, publication-ready insights.
[Service]
Work with native-read sequencing experts with decades of experience in genomics, epigenomics, and bioinformatics to guide your project from discovery to clinical success.
Wasatch BioLabs offers end-to-end custom assay development services that include biomarker discovery, region-specific targeting, assay optimization, and regulatory-grade validation. Whether your goal is research use only (RUO) or clinical deployment (GCP, CLIA, CLEP, FDA), WBL provides tailored workflows to meet your specific project needs.
WBL’s custom assay development process begins with a collaborative planning session to define your therapeutic area and research goals. From there, the team helps you select key targets and develops hybridization- or bioinformatics-driven panels, ensuring your assay is optimized for biological relevance, accuracy, and scalability.
Custom assays can include a wide range of biomarkers such as tissue-specific methylation signatures, structural variants, single nucleotide variants, and regions associated with gene expression or disease states. Wasatch BioLabs can design panels for both genomic and epigenomic features using advanced technologies like dMS, dWMS, and dTMS.
The custom assay development process at WBL generally includes the following stages:
Discovery & Planning – Define research goals and targets
Assay Design – Bioinformatic targeting and probe development
Optimization & Validation – Run test assays and validate endpoints
Deployment – RUO or regulatory-aligned processing
Timelines may vary based on sample complexity and regulatory requirements.
Yes. WBL's custom assays are fully compatible with native-read sequencing platforms like Oxford Nanopore. The assays can also be paired with Wasatch BioLabs’ bioinformatics tools, enabling seamless integration into your existing pipelines for variant detection, methylation profiling, and expression analysis.
Wasatch BioLabs provides fit-for-purpose validation based on your business needs, whether RUO, GCP, CLIA, CLEP, and FDA. Our clinical-grade infrastructure and rigorous quality control frameworks ensure your custom assays meet appropriate regulatory standards and performance benchmarks.
To start a project, contact Wasatch BioLabs directly through our website or email our support team. You'll be connected with expert scientists who will guide you through the planning, design, and implementation stages of your custom assay development—ensuring the solution is precisely aligned with your research or clinical goals.
